Citigroup Maintains Neutral on Moderna, Raises Price Target to $60

Benzinga Newsdesk www.benzinga.com Positive 49.3%

Neg 0% Neu 0% Pos 49.3%

Citigroup analyst Geoff Meacham maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $41 to $60.